These findings indicate that even relatively resistant cells, in vitro, demonstrated sensitivity in vivo in the combined treatment, suggesting PPARĪ³ agonist could potentially be used to sensitize bladder cancer cell lines that were resistant to EGFR inhibition.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}